NovaBridge Biosciences American
NBP
NovaBridge Biosciences American Depositary Shares represent ownership in NovaBridge Biosciences, a biotechnology company founded in 2020 and headquartered in Shanghai, China. The company specializes in developing innovative precision therapies for oncology and immunology indications. Its primary focus centers on next-generation antibody-drug conjugates (ADCs), bispecific antibodies, and protein degraders designed to target difficult-to-treat cancers and autoimmune diseases. NovaBridge Biosciences leverages advanced platforms, including proprietary linker-payload technologies and tumor-targeted delivery systems, to create therapeutics with enhanced efficacy and reduced toxicity profiles. The company advances its pipeline through discovery, preclinical development, and clinical-stage programs, partnering with global pharmaceutical firms to accelerate innovation. These American Depositary Shares enable U.S. investors to access NovaBridge's biotechnology portfolio, which plays a key role in addressing unmet medical needs in the rapidly evolving biopharma sector focused on immuno-oncology and immune modulation.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$88M
▼ -297.4% YoY
Op. Margin
–
ROIC
-33.92%
▼ -14.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$21M
▲ +60.9% YoY
Op. Cash Flow (TTM)
-$21M
▲ +47.2% YoY
Net Debt
-$208M
Net Cash Position
Cash & Equiv.
$211M
Continue Research
Peers
Biotechnology · Pick stocks to compare with NBP
Held by ETFs
NBP is in 4 US ETFs. The largest of them, with NBP's weight in each:
NovaBridge Biosciences American (NBP) in three numbers
Questions about NovaBridge Biosciences American
Is NovaBridge Biosciences American a high-quality business?
NovaBridge Biosciences American scores 18 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$208M, and its weakest is return on capital at -33.9%. The Quality tab shows every check against its target.
Does NovaBridge Biosciences American (NBP) pay a dividend?
No. NovaBridge Biosciences American (NBP) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing NBP
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.